DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury
DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury
Enrolling by invitation · NCT07567274 · Registry updated 2026-05-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury | COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Ear Diseases, Infections, Neurologic Manifestations, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, Sensation Disorders, Signs and Symptoms, hearing disorder, long COVID-19, lung disorder, nervous system disorder, otorhinolaryngologic disease, pneumonia, respiratory system disorder, respiratory tract infectious disorder, tinnitus, viral infectious disease, viral pneumonia | Enrolling by invitation | Phase 2 | 2026-05-13 | NCT07567274 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Leading Edge Clinic | 1 |
| Rebuild Medicine Inc | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nationwide Telemedicine Study (Leading Edge Clinic) | Ithaca | United States | 1 |